Further research and development of GPR65 and NUAK2 inhibitors, improving specificity and minimizing toxicity, could lead to the efficacious targeting of CD4+ T cells in the treatment of IBD.10 This evidence concerns the gene NUAK2 and inflammatory bowel disease.